


Claims


1. A compound, or a pharmaceutically acceptable salt thereof, having the following formula I:



wherein n is an integer from 0-1, and R is elected from the group consisting of hydrogen, C₁₋₁₀ alkyl, C₁₋₁₀ aryl and



2. The compound of claim 1, which has the following formula II:



3. A pharmaceutical composition, which composition comprises the compound of claim 1.

4. The pharmaceutically composition of claim 3, which further comprises a pharmaceutically acceptable carrier or excipient.

5. A method for treating or preventing a disease or disorder caused by *Helicobacter pylori* (*H. pylori*) infection, which method comprises administering, to a subject to which such treatment or prevention is needed or desirable, an effective amount of the compound of claim 1, or a pharmaceutically acceptable salt thereof, thereby said disease or disorder is treated or prevented.

6. The method of claim 5, wherein the subject is a mammal.
7. The method of claim 6, wherein the mammal is a human.
- 5 8. The method of claim 5, which comprises administering the compound of claim 2, or a pharmaceutically acceptable salt thereof, to the subject.
9. The method of claim 5, which comprises administering the pharmaceutical composition of claim 3 to the subject.
- 10 10. The method of claim 5, wherein the disease or disorder caused by *H. pylori* infection to treated or prevented is chronic gastritis, gastroduodenal ulcer, adenocarcinoma of the distal stomach, gastric lymphoma or gastric cancer.
- 15 11. The method of claim 5, wherein the subject is treated without administering an anti-*H. pylori* agent.
12. The method of claim 11, wherein the anti-*H. pylori* agent is proton-pump inhibitor (PPI), metronidazole, clarithromycin or amoxicillin.
- 20 13. The method of claim 5, wherein the *H. pylori* is a resistant strain induced by PPI, metronidazole, clarithromycin or amoxicillin treatment.
14. The method of claim 5, wherein the compound or a pharmaceutically acceptable salt thereof is administered by intracavernous injection, subcutaneous injection, intravenous injection, intramuscular injection, intradermal injection, oral administration, or topical administration.
- 25 15. The method of claim 5, which further comprises a step of diagnosing or pragnosing *H. pylori* infection in the subject.
- 30

16. A combination, which combination comprises the compound of claim 1, or a pharmaceutically acceptable salt thereof, and an anti-*H. pylori* agent.

5 17. The combination of claim 16, wherein the anti-*H. pylori* agent is PPI, metronidazole, clarithromycin or amoxicillin.

10 18. A method for treating or preventing a disease or disorder caused by *H. pylori* infection, which method comprises administering, to a subject to which such treatment or prevention is needed or desirable, an effective amount of the combination of claim 16, or a pharmaceutically acceptable salt thereof, thereby said disease or disorder is treated or prevented.

15 19. A kit, which kit comprises the compound of claim 1, or a pharmaceutically acceptable salt thereof, and an instruction for using said compound or pharmaceutically acceptable salt in treating or preventing a disease or disorder caused by *H. pylori* infection.

20 20. A kit, which kit comprises the combination of claim 15, and an instruction for using said combination in treating or preventing a disease or disorder caused by *H. pylori* infection.